Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present new research data on AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), being held in Orlando, FL, May 29 - June 1. AMPYRA is an FDA-approved therapy indicated to improve walking in people with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.
“The results of the STEADY study being presented at CMSC expand our understanding of how AMPYRA may improve various dimensions of walking in people with MS and guide us towards endpoints for future studies”
"The results of the STEADY study being presented at CMSC expand our understanding of how AMPYRA may improve various dimensions of walking in people with MS and guide us towards endpoints for future studies," said Adrian Rabinowicz, M.D., FAAN, Acorda's Senior Vice President of Clinical Development and Medical Affairs. "We are sponsoring a range of studies aimed at exploring the use of AMPYRA within MS even as we look to potentially expand its use into post-stroke deficits and continue to develop other drugs in our pipeline such as rHIgM22 in MS, GGF2 in heart failure, and Diazepam Nasal Spray for treatment of certain epileptic seizures."
Data being presented on AMPYRA at the CMSC annual meeting include:
-
Effects of Dalfampridine on Gait in Multiple Sclerosis: The STEADY Study - RH16 being presented Thursday, May 30, 6:30pm - 8pm
-
Effects of Dalfampridine on Balance in Multiple Sclerosis: The STEADY Study - RH 17 being presented Thursday, May 30, 6:30pm - 8pm
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy